Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)

NCT06389136 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06389136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06389136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Recruiting
Start date
June 14, 2024
Completion date
March 31, 2027
Enrollment
200 (estimated)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis